Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Penumbra Inc (PEN)

Penumbra Inc (PEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,274,542
  • Shares Outstanding, K 39,162
  • Annual Sales, $ 1,195 M
  • Annual Income, $ 14,010 K
  • EBIT $ 173 M
  • EBITDA $ 197 M
  • 60-Month Beta 0.71
  • Price/Sales 9.32
  • Price/Cash Flow 104.26
  • Price/Book 8.68

Options Overview Details

View History
  • Implied Volatility 12.65% (-41.35%)
  • Historical Volatility 45.82%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 65.18% on 04/08/25
  • IV Low 12.65% on 01/15/26
  • Expected Move (DTE 1) 2.46 (0.70%)
  • Put/Call Vol Ratio 0.54
  • Today's Volume 3,262
  • Volume Avg (30-Day) 472
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 6,176
  • Open Int (30-Day) 3,193
  • Expected Range 348.66 to 353.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.12
  • Number of Estimates 8
  • High Estimate 1.24
  • Low Estimate 0.99
  • Prior Year 0.97
  • Growth Rate Est. (year over year) +15.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
290.00 +21.11%
on 01/13/26
352.14 -0.26%
on 01/15/26
+42.08 (+13.61%)
since 12/15/25
3-Month
221.26 +58.74%
on 11/03/25
352.14 -0.26%
on 01/15/26
+98.62 (+39.04%)
since 10/15/25
52-Week
221.26 +58.74%
on 11/03/25
352.14 -0.26%
on 01/15/26
+89.46 (+34.18%)
since 01/15/25

Most Recent Stories

More News
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Penumbra, Inc. (NYSE: PEN)

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions...

PEN : 350.97 (+11.98%)
Wall Street steadies as chip stocks bounce back and oil prices ease

Wall Street is steadying

BLK : 1,160.26 (+6.27%)
KLAC : 1,545.42 (+7.73%)
NVDA : 186.68 (+1.93%)
AMAT : 320.25 (+6.08%)
AVGO : 342.18 (+0.67%)
CVX : 166.62 (-0.37%)
BAC : 52.55 (+0.13%)
$SPX : 6,945.55 (+0.27%)
MS : 191.25 (+5.79%)
BSX : 90.00 (-3.99%)
GS : 975.17 (+4.56%)
$IUXX : 25,557.94 (+0.36%)
Why Penumbra (PEN) Stock Is Trading Up Today

Why Penumbra (PEN) Stock Is Trading Up Today

PEN : 350.97 (+11.98%)
Stocks Supported by Strength in Chip Makers and US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.49%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.07%. March E-mini S&P futures (ESH26...

BLK : 1,160.26 (+6.27%)
MSTR : 172.34 (-3.90%)
AMAT : 320.25 (+6.08%)
MPC : 177.86 (-1.78%)
SNDK : 413.02 (+6.50%)
ADI : 302.60 (+1.55%)
MLTX : 16.36 (-6.03%)
$IUXX : 25,557.94 (+0.36%)
ASML : 1,333.20 (+5.50%)
ZNH26 : 112-060 (-0.25%)
OXY : 43.37 (-2.14%)
ESH26 : 6,980.00 (+0.20%)
Shareholder Alert: The Ademi Firm investigates whether Penumbra, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE , Jan. 15, 2026 /PRNewswire/ -- Ademi LLP is investigating Penumbra (NYSE: PEN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

PEN : 350.97 (+11.98%)
Stock Indexes Rally on Chip Demand Optimism

The S&P 500 Index ($SPX ) (SPY ) today is up +0.55%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.00%. March E-mini S&P futures (ESH26...

BLK : 1,160.26 (+6.27%)
MSTR : 172.34 (-3.90%)
AMAT : 320.25 (+6.08%)
MPC : 177.86 (-1.78%)
AVGO : 342.18 (+0.67%)
SNDK : 413.02 (+6.50%)
MLTX : 16.36 (-6.03%)
$IUXX : 25,557.94 (+0.36%)
ZNH26 : 112-060 (-0.25%)
OXY : 43.37 (-2.14%)
ESH26 : 6,980.00 (+0.20%)
FANG : 150.54 (-2.08%)
PEN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Penumbra, Inc. is Fair to Shareholders

Shareholders should contact the firm as there may be limited time to enforce your rights.

PEN : 350.97 (+11.98%)
Boston Scientific announces agreement to acquire Penumbra, Inc.

Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases

BSX : 90.00 (-3.99%)
PEN : 350.97 (+11.98%)
Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results

ALAMEDA, Calif. , Jan. 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced certain unaudited and preliminary financial results for the fourth...

PEN : 350.97 (+11.98%)
1 Healthcare Stock to Keep an Eye On and 2 We Ignore

1 Healthcare Stock to Keep an Eye On and 2 We Ignore

PEN : 350.97 (+11.98%)
AMGN : 329.98 (+0.31%)
ADUS : 109.59 (-0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access...

See More

Key Turning Points

3rd Resistance Point 341.67
2nd Resistance Point 329.30
1st Resistance Point 321.36
Last Price 350.97
1st Support Level 301.05
2nd Support Level 288.68
3rd Support Level 280.74

See More

52-Week High 352.14
Last Price 350.97
Fibonacci 61.8% 302.14
Fibonacci 50% 286.70
Fibonacci 38.2% 271.25
52-Week Low 221.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar